HIV Diagnostics Test Market

Molecular Diagnostics is the largest segment driving the growth of HIV Diagnostics Test Market


The global HIV Diagnostics Test Market is estimated to be valued at US$ 14.05 Mn or Million in 2023 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

HIV diagnostics tests help in the detection of HIV in the human body. These tests detect the presence of HIV antibodies or antigens in the blood which confirms HIV infection. These tests play a vital role in screening blood supply, diagnosis, and disease management.

Market key trends:

The increasing adoption of Point of Care (POC) testing devices is one of the major trends witnessed in the HIV diagnostics test market. POC testing devices offer numerous advantages like rapid testing and delivering quick results outside laboratory settings. Companies are focusing on developing integrated diagnostic kits, combining HIV diagnostic tests with other health indicators tests to offer multi-disease screening using a single sample. This reduces the turnaround time and likelihood of losing patients to follow up.

Market key trends:

One of the major trends in the HIV diagnostics test market is the adoption of novel diagnostic technologies. Companies are focusing on developing advanced diagnostic kits and assays that can provide accurate and faster detection of HIV infection. For instance, point-of-care testing kits that provide non-invasive, rapid, and accurate detection of HIV within 30 minutes are gaining popularity. Such advanced diagnostics aid early detection and help in improving treatment outcomes.

SWOT Analysis

Strengths: Rising awareness about HIV diagnostics and improving access to testing.
Weaknesses: High cost of advanced diagnostic technologies limits their use in low and middle-income countries.
Opportunities: Untapped growth potential in developing regions. Launch of novel technologies such as CRISPR-based diagnostics provide new opportunities.
Threats: Stringent regulatory landscape increases compliance challenges for market players. Patent cliffs of blockbuster drugs affects market revenues.

Key Takeaways

The Global HIV Diagnostics Test Market Size was valued at US$ 14.05 Mn in 2023 and is expected to reach US$ 25.02 Mn by 2030, expanding at a CAGR of 9.0% during the forecast period. Rapid growth can be attributed to growing government initiatives for HIV prevention and increasing adoption of advanced diagnostics for early detection.

Regionally, North America dominated the market in 2023 and is expected to continue its dominance during the forecast period. Presence of major market players, availability of advanced diagnostics, and rising awareness regarding benefits of early detection are some factors driving the North American HIV diagnostics market. However, Asia Pacific is anticipated to witness the fastest growth over the forecast period supported by improving access to diagnosis in developing nations like India and China.

Key players operating in the HIV Diagnostics Test market are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol -Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd. Major companies are focused on new product launches, geographic expansion, and strategic collaborations to strengthen their market presence.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it